一、公司首次回购股份的具体情况 2023 年 10 月 27 日，公司实施了首次回购，公司通过集中竞价交易方式首 次回购股份数量为 798,500 股，占公司目前总股本的比例为 0.1713%，成交的最 低价格为人民币 16.13 元/股，成交的最高价格为人民币 17.00 元/股，支付的总金 额为人民币 13,337,842.00 元（不含交易费用），本次回购符合公司回购方案及相 关法律法规的要求。 证券代码：300119 证券简称：瑞普生物 公告编号：2023-071 天津瑞普生物技术股份有限公司 关于首次回购公司股份的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 天津瑞普生物技术股份有限公司（以下简称"公司"）于 2023 年 10 月 26 日召开第五届董事会第十次（临时）会议，审议通过了《关于回购公司股份方案 的议案》，同意公司使用自有资金以集中竞价交易方式回购公司无限售条件的 A 股流通股，用于股权激励或员工持股计划。本次回购资金总额不低于人民币 4,000.00 万元、不超过人民币 8,000.00 万元。回购股份的价格不超过人民币 18 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2023-069 二、公司前十名无限售条件股东持股情况 天津瑞普生物技术股份有限公司 关于回购股份事项前十名股东及前十名无限售条件股东持股情 况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 天津瑞普生物技术股份有限公司（以下简称"公司"）于 2023 年 10 月 26 日召开第五届董事会第十次（临时）会议，审议通过了《关于回购公司股份方案 的议案》。公司拟使用自有资金以集中竞价交易方式回购公司发行的人民币普通 股股份，用于后续实施股权激励或员工持股计划，具体内容详见公司于 2023 年 10 月 27 日在深圳证券交易所网站（http://www.szse.cn）及巨潮资讯网 （http://www.cninfo.com.cn）披露的《关于回购公司股份方案的公告》（公告 编号：2023-068）。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规定，现将董事会公告回购股份决议的前一个交易日 （即 2023 年 10 月 25 日）登记在册的前十名股 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2023-070 天津瑞普生物技术股份有限公司 股份回购报告书 重要内容提示： 1、天津瑞普生物技术股份有限公司（以下简称"公司"）拟使用自有资金以 集中竞价交易方式回购公司无限售条件的A股流通股（以下简称"本次回购"）， 用于股权激励或员工持股计划。本次回购资金总额不低于人民币4,000.00万元、 不超过人民币8,000.00万元，回购股份的价格不超过人民币18.00元/股。按照本 次回购金额上限不超过人民币8,000.00万元，回购价格上限不超过人民币18.00 元/股进行测算，回购数量约为444.44万股，回购股份比例约占公司总股本的 0.95%。按照本次回购金额下限不低于人民币4,000.00万元，回购价格上限不超 过人民币18.00元/股进行测算，回购数量约为222.22万股，回购股份比例约占公 司总股本的0.48%，具体回购股份的数量以回购结束时实际回购的股份数量为准。 本次回购股份的实施期限为自公司董事会审议通过本回购股份方案之日起不超 过3个月。 2、本次回购股份方案已经公司于2023年10月26日召开的第五届董事会第十 次（临时）会议审 ...

Company Overview and Development - Founded in 1998, the company has 25 years of experience in the animal health industry, focusing on "Animal and Human Health" [2] - The company has over 500 veterinary drug approvals and feed additive filings, covering products for pigs, chickens, waterfowl, cattle, sheep, and pets [2] - It is one of the largest and most comprehensive veterinary drug companies in China, also a major producer of vaccines for significant animal diseases [3] R&D and Innovation - The company has gone through three R&D stages: cooperative innovation, balanced innovation, and independent innovation [3] - It operates five research institutes with a total R&D investment of 1.1 billion yuan over the past decade, resulting in numerous awards and over 200 patented technologies [3] - The company has established long-term strategic partnerships with more than 30 renowned research institutions globally [3] Disease Detection and Prevention - Established the Bohai Agriculture and Animal Husbandry Disease Diagnosis and Testing Platform, providing free testing of 600,000 samples in 2022 [3] - The platform helps in precise disease prevention, immune effect evaluation, and disease trend analysis through gene sequencing [3] Market Focus and Product Layout - Initially focused on the poultry sector, now leading in product variety, quality, and market share [4] - Expanding into the livestock sector with a focus on core products and market penetration [4] - The pet sector is a growing market, with China's pet consumption market exceeding 270 billion yuan in 2022, and the company has developed over 20 pet vaccines and drugs [4] Marketing Strategies - Utilizes three main marketing models: government bidding, direct sales to large clients, and a distributor network [4] - The company's H5+H7 avian influenza vaccine is included in the national government bidding list [4] - Plans to transition from government bidding to market-based procurement by 2025 [4] Product Advantages - The company's cat triple vaccine is among the first in China to pass the Ministry of Agriculture's emergency evaluation, with high safety and efficacy levels [4] - It has established a unique channel advantage, collaborating with major pet hospitals and supply chain companies [4] Financial and Operational Efficiency - Implemented cost reduction and efficiency improvement measures, including process optimization and lean production [5] - Conducted organizational restructuring to streamline management layers and enhance efficiency [5] Share Repurchase Plan - The company announced a share repurchase plan to demonstrate confidence in future prospects and enhance investor confidence [5] - The repurchased shares will be used for employee stock ownership plans or equity incentives [5]

证券代码：300119 证券简称：瑞普生物 公告编号：2023-068 天津瑞普生物技术股份有限公司 重要内容提示： 天津瑞普生物技术股份有限公司（以下简称"公司"）拟以集中竞价交易方 式回购公司股份，主要内容如下： 1、回购股份的种类：无限售条件的 A 股流通股。 关于回购公司股份方案的公告 2、回购股份的用途：拟用于股权激励或员工持股计划。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 6、回购期限：回购股份的实施期限为自董事会审议通过回购股份方案之日 起 3 个月内。 7、回购股份的数量占公司总股本的比例： 按照本次回购金额上限不超过人民币 8,000.00 万元，回购价格上限不超过 人民币 18.00 元/股进行测算，回购数量约为 444.44 万股，回购股份比例约占公 司总股本的 0.95%。按照本次回购金额下限不低于人民币 4,000.00 万元，回购 价格上限不超过人民币 18.00 元/股进行测算，回购数量约为 222.22 万股，回购 股份比例约占公司总股本的 0.48%。 8、相关股东是否存在减持计划： 经自查，公司控股股东、实际控制人及 ...

天津瑞普生物技术股份有限公司 独立董事对第五届董事会第十次（临时）会议 相关事项的独立意见 我们作为天津瑞普生物技术股份有限公司（以下简称"公司"）的独立董事,参 加了 2023 年 10 月 26 日召开的第五届董事会第十次（临时）会议，根据《深圳 证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有关法律、法规、规范性文件以及《公司章 程》的规定，我们对公司本次董事会的相关事项进行了认真审议，现就相关事项 发表专项意见如下： 1、本次公司回购股份的方案符合《公司法》《证券法》《深圳证券交易所 上市公司自律监管指引第 9 号——回购股份》等法律法规、规范性文件及《公司 章程》的有关规定，审议该事项的董事会审议程序合法、合规。 独立董事：才学鹏、郭春林、周睿 二〇二三年十月二十六日 1 2、本次回购股份用于股权激励或员工持股计划，能充分调动公司员工的积 极性和创造性，进一步完善公司长效激励机制，提高员工凝聚力和公司竞争力， 有利于提升投资者对公司的信心，维护中小股东利益，促进公司的长远健康发展。 3、公司本次回购股份的资金来自公司自有资金，不会对公司经营 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2023-067 天津瑞普生物技术股份有限公司 第五届董事会第十次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 基于对公司未来发展前景的信心以及对公司价值的高度认可，为维护广大投 资者的利益，增强投资者信心，同时完善公司长效激励机制，充分调动公司管理 人员、核心骨干的积极性，提高团队凝聚力和竞争力，有效推动公司的长远发展， 经充分考虑业务发展前景、经营情况、财务状况、未来盈利能力等因素，公司拟 使用自有资金以集中竞价方式回购公司股份，回购的公司股份拟用于股权激励或 员工持股计划。本次回购的股份应当在本次回购完成后三年内实施上述用途，如 公司未能按上述用途实施，则尚未使用的已回购股份将依法注销并减少注册资本。 表决结果：9 票同意，0 票反对，0 票弃权。 2、回购股份符合相关条件 本次回购事项符合《上市公司股份回购规则》第七条以及《深圳证券交易 所上市公司自律监管指引第 9 号—回购股份》第十条相关规定： （1）公司股票上市已满一年； 一、董事会会议召开情况 天津瑞普生物技术股份有限 ...

1、请问猫三联疫苗的推进情况？ 回复：公司自主研发的猫三联疫苗在今年 8 月份通过了农 业农村部应急评价，是国内最早一批通过应急评价的国产猫疫 苗产品，与公司产品研发申报的预期相符。目前，公司正在组 织猫三联的复核检验，推动产品尽快上市。该产品所用毒株均 采用国内流行毒株，市场匹配度高，在今年 4 月份已完成临床 试验，公司正在进行扩大性试验，保障产品的安全性和有效 性。产品上市后，将借助瑞派宠物医院、中瑞供应链及核心经 销商的渠道快速推向市场。 2、公司在宠物产品方面的布局有哪些？ 回复：公司在宠物产品上布局多年，已形成了以驱虫药、 麻醉药、耳药、抗生素为代表的二十余款系列产品，储备了猫 三联疫苗、犬四联疫苗、复方二氯苯醚菊酯吡丙醚滴剂等产 品，通过自主开发、合作研发等多种方式布局宠物诊断试剂、 治疗性抗体、多组分复方驱虫药等领域，为打造宠物全产品矩 阵蓄能。 3、公司前三季度研发费用同比增长超过 60%，请问主要原 因是？ 证券代码：300119 证券简称：瑞普生物 天津瑞普生物技术股份有限公司投资者关系活动记录表 编号：2023-006 | | □特定对象调研 □ 分析师会议 | | --- | --- ...

Financial Performance - The company's revenue for Q3 2023 reached ¥593,068,520.22, representing a 4.34% increase compared to the same period last year[5]. - Net profit attributable to shareholders was ¥95,426,859.38, up 2.40% year-on-year, while the net profit after deducting non-recurring gains and losses was ¥81,132,930.17, an increase of 0.50%[5]. - Total operating revenue for the current period reached ¥1,587,164,776.49, an increase of 7.5% compared to ¥1,476,760,957.48 in the previous period[28]. - Net profit for the current period was ¥294,900,963.96, representing a 15.3% increase from ¥256,016,202.77 in the same period last year[29]. - The company reported a total comprehensive income of ¥294,900,963.96, an increase from ¥256,016,202.77 in the same period last year[30]. - Earnings per share (EPS) improved to ¥0.5900, compared to ¥0.5036 in the previous year[30]. Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥6,218,503,041.23, reflecting a 1.84% increase from the end of the previous year[5]. - Current assets totaled CNY 3,038,546,011.31, a decrease from CNY 3,093,291,712.42 at the beginning of the year[24]. - The company’s total liabilities decreased to CNY 1,572,707,220.68 from CNY 1,605,173,462.21 at the beginning of the year[26]. - The ending balance of cash and cash equivalents was 382,399,123.95, down from 620,788,270.41 year-over-year[34]. Cash Flow - Cash flow from investment activities was ¥159,367,086.50, a 116.73% increase, primarily due to the redemption of financial products and increased investment income[10]. - Cash inflow from investment activities totaled ¥2,756,212,231.59, a significant increase from ¥1,583,477,199.71 year-over-year[33]. - Cash flow from operating activities generated a net amount of ¥196,967,341.28, slightly down from ¥200,918,377.93 in the prior period[33]. - The net cash flow from financing activities showed a significant decline, amounting to -¥350,695,043.06, a decrease of 481.22% due to the repayment of bank loans[10]. Research and Development - Research and development expenses surged to ¥124,183,791.04, marking a 66.84% increase, driven by enhanced R&D efforts and talent acquisition[9]. - Research and development expenses increased significantly to ¥124,183,791.04, a rise of 67% from ¥74,433,917.50 year-over-year[28]. - The company has developed a new inactivated vaccine for cats, which has passed emergency evaluation by the Ministry of Agriculture and Rural Affairs[17]. - The company obtained two new veterinary drug registration certificates, enhancing its product matrix in bacterial genetic engineering vaccines and disinfection, creating new profit growth points[18]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 17,890[12]. - The largest shareholder, Li Shoujun, holds 35.92% of shares, totaling 167,474,479 shares, with 48,500,000 shares pledged[12]. - The company has 125,605,859 shares under lock-up for executives, which will remain until the end of the lock-up period[15]. - The top ten shareholders include various institutional and individual investors, with significant pledges noted[12]. - The controlling shareholder and actual controller committed not to reduce their holdings in the company for six months, reflecting confidence in the company's future development[19]. Operational Developments - The company is actively organizing trial production and applying for temporary approval for the new veterinary drug[17]. - The company is focused on expanding its product offerings and market presence in the veterinary sector[17]. - The company’s subsidiary, Hunan Zhong'an, sold part of its assets to enhance asset liquidity and positively impact operational results[21]. Other Financial Metrics - The weighted average return on net assets was 2.21%, a slight decrease of 0.08% compared to the previous year[5]. - The company’s total equity attributable to shareholders increased to ¥4,360,872,233.93, up 3.30% from the end of the previous year[5]. - The company experienced a 271.88% increase in notes receivable, reaching ¥14,797,012.02, attributed to increased note business during the period[9]. - The adjustment of deferred tax liabilities was from 52,443,981.15 to 52,437,603.03 due to the new accounting standards implemented in 2023[36]. - The adjustment of payable taxes increased slightly from 47,476,720.17 to 47,483,098.29[36]. Stock and Capital Changes - The company completed the repurchase and cancellation of 1.7426 million restricted stock options, resulting in a total share capital of 466,276,186 shares[22]. - The total number of restricted shares at the beginning of the period was 133,711,900, with 1,742,600 shares released during the period[16]. - The company has a total of 131,979,425 restricted shares remaining after the recent adjustments[16]. Audit Status - The third quarter report was not audited[37].

证券代码：300119 证券简称：瑞普生物 公告编号：2023-064 天津瑞普生物技术股份有限公司 2023 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1、本次股东大会无变更、否决议案的情况； 2、本次股东大会以现场投票、网络投票相结合的方式召开。 一、会议召开和出席情况 天津瑞普生物技术股份有限公司（以下简称"公司"）2023年8月26日以董事会 公告方式向全体股东发出召开2023年第二次临时股东大会的通知。（公告编号：2023- 055）。 本次股东大会采取现场投票、网络投票相结合的方式召开。其中现场会议于2023 年9月11日下午15:00在公司会议室召开，会议由董事长李守军先生主持；通过深圳 证券交易所系统进行网络投票的时间为2023年9月11日09:15-09:25，09:30-11:30， 13:00-15:00；通过深圳证券交易所互联网系统投票的具体时间为2023年9月11日 09:15-15:00期间的任意时间。 二、议案审议表决情况 本次股东大会以现场记名投票、网络投票表决的方式，审议了以下议 ...